Hyperoside

The most reproduced organ signal. In a rat model of hepatic ischaemia-reperfusion, isolated hyperoside reduced liver injury by suppressing oxidative stress and inhibiting apoptosis (lower MDA, preserved antioxidant enzymes, shifted Bax/Bcl-2) ^{6Reference 6Shi Y et al. · 2019AnimalHyperoside Attenuates Hepatic Ischemia-Reperfusion Injury by Suppressing Oxidative Stress and Inhibiting Apoptosis in Rats — rat in vivo animal modelView study →}. In a 12-week non-alcoholic fatty liver disease (NAFLD) rat model, hyperoside improved hepatic steatosis while remodelling the gut microbiota and reprogramming serum metabolites — a mechanism that fits its poor absorption and heavy gut-level exposure ^{9Reference 9Huang M et al. · 2025AnimalHyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks — rat in vivo animal modelView study →}. Reviews collect further hepatoprotective activity across chemical- and immune-injury models ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →2Reference 2Wang K et al. · 2023ReviewPotential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review — reviewView study →}.

Gap: all rat/cell models with no human dosing; because hyperoside is largely hydrolysed to quercetin before absorption, part of any systemic hepatoprotection may be a quercetin-metabolite effect rather than the intact glycoside ^{3Reference 3Yang J et al. · 2013In vitroIdentification of the major metabolites of hyperoside produced by the human intestinal bacteria using the ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry — in vitro human gut microbiotaView study →}.

Two complementary lines, both isolated hyperoside. In primary rat cortical neurons, hyperoside protected against amyloid-β toxicity by engaging the PI3K/Akt/Bad/Bcl-XL axis and preserving mitochondrial integrity — an anti-apoptotic, pro-survival mechanism ^{4Reference 4Zeng KW et al. · 2011In vitroHyperoside protects primary rat cortical neurons from neurotoxicity induced by amyloid β-protein via the PI3K/Akt/Bad/Bcl-XL-regulated mitochondrial apoptotic pathway — in vitroView study →}. In LPS-activated microglia, it suppressed nitric oxide and pro-inflammatory cytokine production via p38 MAPK and NF-κB inhibition, i.e. a neuroinflammation-damping action ^{5Reference 5Fan HH et al. · 2017In vitroHyperoside inhibits lipopolysaccharide-induced inflammatory responses in microglial cells via p38 and NFκB pathways — in vitroView study →}. Reviews add antioxidant and vasoprotective signals in cerebral ischaemia-reperfusion models ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →2Reference 2Wang K et al. · 2023ReviewPotential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review — reviewView study →}.

Gap: cell and rodent only, with no human cognitive or stroke data; brain exposure of an intact, poorly-absorbed flavonol glycoside is a real barrier, so the in-vivo relevance of the neuron-level concentrations is unproven ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →3Reference 3Yang J et al. · 2013In vitroIdentification of the major metabolites of hyperoside produced by the human intestinal bacteria using the ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry — in vitro human gut microbiotaView study →}.

Isolated hyperoside is cardioprotective in myocardial ischaemia-reperfusion. Preconditioning rat hearts with hyperoside improved contractile recovery, cut infarct size, lowered CK/CK-MB leakage and TNF-α/IL-6, and shifted Bax/Bcl-2 toward survival — effects abolished when the PI3K/Akt pathway was blocked with LY294002, confirming that pathway as the mediator ^{7Reference 7Han J et al. · 2015AnimalProtective effect against myocardial ischemia reperfusion injuries induced by hyperoside preconditioning and its relationship with PI3K/Akt signaling pathway in rats — rat in vivo animal modelView study →}. Reviews describe hyperoside as having “very low toxicity in the effective dose range” for cardiac endpoints ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →}.

Gap: single-mechanism rodent IR work; no human cardiac data, and the systemic exposure achievable from an oral glycoside is not addressed by these preconditioning experiments ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →7Reference 7Han J et al. · 2015AnimalProtective effect against myocardial ischemia reperfusion injuries induced by hyperoside preconditioning and its relationship with PI3K/Akt signaling pathway in rats — rat in vivo animal modelView study →}.

A genuinely double-edged organ. In type-2 diabetic mice, isolated hyperoside reduced albuminuria and mesangial expansion and suppressed renal inflammation by shifting macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype (lower MCP-1, TNF-α, iNOS) ^{8Reference 8Liu J et al. · 2021AnimalHyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus — mouse in vivo animal modelView study →}. But pharmacokinetic work shows hyperoside accumulates in the kidney, and reviews explicitly warn that long-term high-dose hyperoside should be avoided because of renal toxicity ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →} — so the same organ that shows a therapeutic signal is also the dose-limiting one.

Gap: the nephroprotective data are a single diabetic-mouse model, directly countered by a documented high-dose nephrotoxicity ceiling; the therapeutic window in the kidney is unestablished ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →8Reference 8Liu J et al. · 2021AnimalHyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus — mouse in vivo animal modelView study →}.

The broadest but thinnest tier. Beyond the microglial anti-inflammatory work above, reviews catalogue anti-inflammatory, antiviral and anticancer activity for isolated hyperoside across many cultured systems, typically at high micromolar concentrations, with scattered in-vivo support ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →2Reference 2Wang K et al. · 2023ReviewPotential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review — reviewView study →}.

Gap: most of this is in-vitro at concentrations the poor oral bioavailability makes hard to reach systemically; in-vivo tumour work is sparse and there are no human oncology or anti-inflammatory data for the isolated molecule ^{1Reference 1Xu S et al. · 2022ReviewHyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity — reviewView study →2Reference 2Wang K et al. · 2023ReviewPotential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review — reviewView study →}.